US Pharma MarketingGeographic atrophy biotech Aviceda to shut down after Phase 2 fail
Aviceda Therapeutics has shut down after AVD-104 failed a Phase 2b trial vs. Astellas Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the…
Aviceda Therapeutics, a biotech that had planned to take an eye drug into Phase 3 this year despite a mid-stage clinical setback, is in the process of winding down, a source familiar with the decision ...
Source: Endpoints News